BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Micro Laboratories, Inc. (MLAR) (OTC Bulletin Board: MLAR) Puts Tasker Capital Group (OTC Bulletin Board: TKER) On Patent Infringement Notice


11/1/2005 12:19:26 PM

JOHNSTON, R.I., Nov. 1 /PRNewswire-FirstCall/ -- Chairman of Micro Laboratories, Inc., Robert Thistle, stated that Vice President Jim Burns of Tasker recently received a letter from federal trial attorney Declan Joseph O'Donnell. The letter stated that Chairman Robert Thistle had met with Mr. Burns to discuss the blatant violations of patent #6,071,500 and that the legal remedies for this infringement are severe, and Tasker may be compelled to disgorge revenues and pay damages with interest fees and cost. Quoting directly from the letter received, "This is a demand for fair compensation for product sold to date and a demand that you cease and desist selling unlicensed products under our patents, including #6,071,500, forthwith."

Thistle says there is clear evidence of patent infringement.

Safe Harbor Act Disclaimer:

This press release contains statements which are forward-looking statements within the meaning of applicable federal securities laws and are based upon the Company's current expectations and assumptions which are subject to a number of risks and uncertainties which could cause actual results to materially differ from those anticipated.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

Micro Laboratories, Inc.

CONTACT: Dr. Robert Thistle, Micro Laboratories, +1-401-349-0001



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES